These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9437202)

  • 1. Cholesterol reduction and clinical benefit. Are there limits to our expectations?
    Fager G; Wiklund O
    Arterioscler Thromb Vasc Biol; 1997 Dec; 17(12):3527-33. PubMed ID: 9437202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
    JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol reduction yields clinical benefits: meta-analysis including recent trials.
    Gould AL; Davies GM; Alemao E; Yin DD; Cook JR
    Clin Ther; 2007 May; 29(5):778-794. PubMed ID: 17697899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Projected coronary heart disease risk benefit with ezetimibe.
    Davies GM; Cook JR; Erbey J; Alemao E; Veltri EP
    Atherosclerosis; 2005 Apr; 179(2):375-8. PubMed ID: 15777556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.
    Mabuchi H; Koizumi J; Shimizu M; Kajinami K; Miyamoto S; Ueda K; Takegoshi T
    Am J Cardiol; 1998 Dec; 82(12):1489-95. PubMed ID: 9874053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in serum total cholesterol and risks of coronary events and cerebral infarction in Japanese men: the Kyushu Lipid Intervention Study.
    Sasaki J; Arakawa K; Iwashita M; Matsushita Y; Kono S;
    Circ J; 2003 Jun; 67(6):473-8. PubMed ID: 12808261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study.
    Paragh G; Márk L; Zámolyi K; Pados G; Ofner P
    Clin Drug Investig; 2007; 27(9):647-60. PubMed ID: 17705573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin trials and goals of cholesterol-lowering therapy after AMI.
    Pedersen TR
    Am Heart J; 1999 Aug; 138(2 Pt 2):S177-82. PubMed ID: 10426879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
    Coukell AJ; Wilde MI
    Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of high serum cholesterol and related disorders in patients at risk for coronary heart disease.
    Grundy SM
    Am J Med; 1997 Feb; 102(2A):15-22. PubMed ID: 9217581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of lowering serum cholesterol on coronary heart disease risk.
    Rossouw JE
    Med Clin North Am; 1994 Jan; 78(1):181-95. PubMed ID: 8283930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Need to change the direction of cholesterol-related medication--a problem of great urgency].
    Okuyama H
    Yakugaku Zasshi; 2005 Nov; 125(11):833-52. PubMed ID: 16272805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does lowering serum cholesterol levels lower coronary heart disease risk?
    Rossouw JE; Rifkind BM
    Endocrinol Metab Clin North Am; 1990 Jun; 19(2):279-97. PubMed ID: 2192874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia.
    Matsuzaki M; Kita T; Mabuchi H; Matsuzawa Y; Nakaya N; Oikawa S; Saito Y; Sasaki J; Shimamoto K; Itakura H;
    Circ J; 2002 Dec; 66(12):1087-95. PubMed ID: 12499611
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.